Claris Bio raised $118 million to advance a pivotal phase 3 trial of its rare corneal disease candidate CSB-001, an eye drop solution of oremepermin alfa, for the treatment of limbal stem cell deficiency (LSCD), a rare condition that depletes the cornea’s regenerative stem cells and can lead to severe vision loss with no therapeutic treatment currently available.
Investment Amount (In Millions) : 118